Akouos LLC (AKA: Akouos Inc) Profile last edited on: 6/12/2024
CAGE: 7NJN1
UEI: Q8ENRG23NEM3
Business Identifier: Restoring and preserving hearing: developing precision therapies for forms of sensorineural hearing loss 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 08
County: Suffolk
Congr. District: 08
County: Suffolk
Public Profile
In early December 2022 it was announced that Eli Lilly had completed acquisition of Akouos LLC. With ties to Harvard and Mass Eye and Ear, founded by major players in the fields of neurotology, inner ear drug delivery, clinical genetics, and AAV gene therapy, since startup Akouos has been focused on treating hearing disorders with clear etiology in genetically-defined patient populations. The firm's ability to match precision therapies with the right patients is rooted in their understanding of hearing loss genetics and pathophysiology. To underpin launch of the firm, Akouos entered into strategic license agreements with Lonza and with Massachusetts Eye and Ear for exclusive rights to the Anc-AAV gene therapy platform for all hearing and balance disorders. The firm's name - ????? in Greek - translates to "Listen" in English
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
100-149Revenue Range
10M-15MVC funded?
YesPublic/Private
Publicly TradedStock Info
NASDAQ : AKUSIP Holdings
25-49Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2017 | 1 | NIH | $223,568 | |
| Project Title: Minimally Invasive Delivery System for Treatment of Inner Ear Disorders | ||||
Key People / Management
Emmanuel John (Manny) Simons -- CEO, President and Co-Founder
Michael J McKenna -- Chief Medical Officer
William F Sewell
Richard J Smith D
Luk H Vandenberghe
Jennifer Wellman -- Senior Vice President, Regulator
Michael J McKenna -- Chief Medical Officer
William F Sewell
Richard J Smith D
Luk H Vandenberghe
Jennifer Wellman -- Senior Vice President, Regulator
